Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) shares were up 8% during trading on Friday . The company traded as high as $2.06 and last traded at $2.04. Approximately 2,762,939 shares were traded during trading, an increase of 12% from the average daily volume of 2,474,208 shares. The stock had previously closed at $1.89.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Wedbush restated an "outperform" rating and set a $5.00 target price on shares of Nuvation Bio in a report on Monday, March 3rd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Finally, HC Wainwright lowered their target price on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $8.00.
Check Out Our Latest Stock Analysis on Nuvation Bio
Nuvation Bio Trading Up 14.1 %
The stock has a market cap of $721.94 million, a P/E ratio of -0.98 and a beta of 1.47. The stock has a 50 day simple moving average of $2.39 and a 200 day simple moving average of $2.58.
Institutional Investors Weigh In On Nuvation Bio
A number of institutional investors have recently modified their holdings of NUVB. Forum Financial Management LP purchased a new position in Nuvation Bio during the 4th quarter worth $29,000. Cerity Partners LLC purchased a new position in shares of Nuvation Bio in the fourth quarter valued at $31,000. Russell Investments Group Ltd. boosted its position in shares of Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after acquiring an additional 15,791 shares during the period. Abacus Planning Group Inc. bought a new position in shares of Nuvation Bio in the fourth quarter worth $44,000. Finally, Cibc World Markets Corp bought a new stake in shares of Nuvation Bio during the 4th quarter valued at about $45,000. 61.67% of the stock is owned by institutional investors.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
See Also
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
